Pfizer and BioNTech have submitted trial data for their Covid-19 vaccine in children aged five to 12 to the US Food and Drug Administration (FDA). The move comes after the companies reported positive results from a Phase II/III trial earlier this month. In the trial, the Covid-19 vaccine demonstrated a favourable safety profile and triggered strong antibody responses among participants. Pfizer and BioNTech plan to submit an Emergency Use Authorization (EUA) request in the coming weeks.
Sanofi will not continue development of its Covid-19 mRNA vaccine candidate despite reporting positive results in a Phase I/II study. The company said the decision was taken after concluding that there will be adequate supply of mRNA-based Covid-19 vaccines in the market going forward. Instead, Sanofi will work with GSK to complete the final development steps of its Covid-19 recombinant vaccine candidate. The company’s mRNA resources will be directed to its new mRNA Center of Excellence to address future pandemics and areas of strong unmet need, Sanofi said.
A new report by UK trade association the Association of the British Pharmaceutical Industry (ABPI) has found that the Covid-19 pandemic had a negative impact on research of other diseases, including cancer, heart disease and diabetes. The report added that clinical trials were halted in the early stages of the pandemic and the disruptions continued in the months since. Research efforts in the UK are recovering, albeit at a lower level compared to some other similar European countries.